Skip to Content

Smith & Nephew PLC ADR

SNN: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$26.00PgvjhjlYhkrzwmrc

Smith & Nephew Aims to Press Its Advantage in the Ambulatory Surgical Setting

Business Strategy and Outlook

Impressive innovation has allowed Smith & Nephew to carve out a slice of the orthopedic, sports medicine, and wound-care markets. Though the company is smaller than the dominant orthopedic competitors, it has punched above its weight in terms of introducing meaningful innovation with its pioneering hip resurfacing implant and knee replacements with Verilast technology, which it contends can last for 30 years. These are significant improvements that exceed the evolutionary innovation typically seen in orthopedics.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of SNN so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center